Repros Reports Positive Clinical Data for Vaginal Proellex® in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
April 12, 2016 16:01 ET
|
Repros Therapeutics Inc.
Primary endpoint of induction of amenorrhea met for both vaginal doses compared to placebo, p<0.0011Proellex®-treated subjects reported a median 100% reduction in diary reports of menstrual...
Repros Announces Initiation of Formal Approval Process by the European Medicines Agency
March 15, 2016 16:01 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, March 15, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it has formally activated the process for obtaining marketing authorization...
Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2015 Financial Results
March 14, 2016 09:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, March 14, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the fourth quarter and year ended December 31, 2015. ...
Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men
February 16, 2016 16:01 ET
|
Repros Therapeutics Inc.
Phase 2 proof of concept study in obese men to assess drug impact on metabolic and quality of life parameters under a rigorous diet and exercise regimen Analyses at 3, 6 and 12 month time...
Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism
February 08, 2016 16:01 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Feb. 08, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that on February 4, 2016, the Company attended a productive meeting with FDA...
Repros Announces Court of Appeals’ Affirmation of Summary Judgment in Favor of the Company
January 11, 2016 09:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the United States Court of Appeals for the Federal Circuit summarily affirmed...
Repros Updates Enclomiphene Program
January 04, 2016 16:05 ET
|
Repros Therapeutics Inc.
Repros expects to meet with FDA to discuss “Complete Response Letter” for enclomiphene NDA during February 2016Marketing Authorization Application (MAA) for enclomiphene planned for submission in...
Repros Updates Proellex® Program
December 21, 2015 16:05 ET
|
Repros Therapeutics Inc.
Topline results after first four months of treatment from all three Proellex® trials expected to be available by end of Q3’16Screening for low dose study for oral Proellex® for uterine fibroids...
Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene
December 01, 2015 09:50 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it has received a Complete Response Letter from the U.S. Food and Drug...
Repros Therapeutics Completes Randomization of Phase 2b Study of Vaginal Proellex(R) in Women With Symptomatic Uterine Fibroid Bleeding
November 12, 2015 16:05 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has completed randomization for its Phase 2b study of Proellex® in the...